Compare the Efficacy and Safety of Beta-Glucan as Add-On to Statin in Subjects With Hyperlipidemia.

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 263 participants.

Also called NCT03857256

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 263 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03857256
Other papers using this trial's data
  • Supplementation with a β-glucan tablet has no effect on hyperlipidemia: a randomized, placebo-controlled clinical trial The American journal of clinical nutrition, 2023-06 DOI, PubMed 37054888

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03857256. Randomized; quadruple masking; primary purpose treatment. Start 2019-05-31 (actual); primary completion 2021-08-31 (actual). Results posted on 2024-01-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Compare the Efficacy and Safety of Beta-Glucan as Add-On to Statin in Subjects With Hyperlipidemia.
Acronym
BetAvena
Condition
Hyperlipidemias
Intervention (Drug)
CP105F
Intervention (Drug)
Placebo
Lead sponsor
Montreal Heart Institute (class: other)
Collaborator
Ceapro Inc. (class: industry)
Collaborator
The Montreal Health Innovations Coordinating Center (MHICC) (class: other)

Record details

Record id
cardio:ct-nct03857256
Content hash
fe7fc86246ca305cc79a10741dbc33d7267a39cffcfcc0e7554cb57a8b5c8d74